The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $1,709,050 were sold by Kumar Neil on Jul 02 ’25. At $42.73 per share, Kumar Neil sold 40,000 shares. The insider’s holdings dropped to 955,686 shares worth approximately $44.14 million following the completion of this transaction.
Also, Kumar Neil sold 40,000 shares, netting a total of over 1,701,400 in proceeds. Following the sale of shares at $42.54 each, the insider now holds 975,686 shares.
Before that, VIKING GLOBAL INVESTORS LP had sold 3,500,000 shares from its account. In a trade valued at $154,000,000, the 10% Owner traded BridgeBio Pharma Inc shares for $44.00 each. Upon closing the transaction, the insider’s holdings decreased to 3,500,000 shares, worth approximately $857.07 million.
As published in their initiating research note from Truist on July 21, 2025, BridgeBio Pharma Inc [BBIO] has been a Buy and the price target has been revised to $66. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid July. As of July 09, 2025, Oppenheimer has increased its “Perform” rating to a “an Outperform” for BBIO. Earlier on June 17, 2025, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for BBIO stock.
Analyzing BBIO Stock Performance
On last trading session,, BridgeBio Pharma Inc [NASDAQ: BBIO] rose 0.92% to $46.19. The stock’s lowest price that day was $45.36, but it reached a high of $47.045 in the same session. During the last five days, there has been a drop of approximately -1.93%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 76.37%. Shares of the company reached a 52-week high of $48.68 on 07/14/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 45.35, which, if violated, would cause prices to drop to 44.51. In the upper region, resistance lies at 47.04. The next price resistance is at 47.88. RSI (Relative Strength Index) is 63.02 on the 14-day chart, showing neutral technical sentiment.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-06-30 dropping by -0.16 million shares to 21.83 million. Data from Yahoo Finance shows that the short interest on 2025-05-30 was 21.99 million shares. A decline of -0.72% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.5 of the overall float, the days-to-cover ratio (short ratio) decline to 6.5.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 57.31% from the previous closing price of $45.77. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $50.
